Similar to SLR14 treatment, we treated SARS-CoV-2–infected K18-hACE2 mice i.v. with low-dose rIFN-αA/D, high-dose rIFN-αA/D, or diABZI 4 h after infection and monitored their disease progression (Fig. 3 A). This evidence concerns the gene KRT18 and infection.